OMER

Rating neutralAI Memo

Omeros

As of 2026-10-25/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-25 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

European narsoplimab refusal narrows the commercial case • 2026-10-16

Base target: $17 / p=45% prob

Biggest risk

The confirmed CHMP refusal removes routine EU access from the near-term case. U.S. launch demand could normalize after the first full quarter, while reimbursement, supply, clinical expansion and cash requirements remain uncertain. [#IR-2026-10-16] Source: https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Receives-CHMP-Negative-Opinion-Following-Re-Examination-of-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Sustained U.S. YARTEMLEA uptake, reimbursement support and cash conversion could offset part of the lost European opportunity. Omeros says Novo Nordisk acquired global zaltenibart rights under their asset-purchase and licensing agreement; the earlier 2025 relationship observation alone did not establish closing, and no future milestone value is assumed here. [#IR-2026-08-12] [#IR-2026-10-16] [#REL-4c1bb65b-6efa-4e21-815b-3c9c07e42240] Sources: https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results/default.aspx ; https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Receives-CHMP-Negative-Opinion-Following-Re-Examination-of-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx ; https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-25

Base target

$17

p=45%

Bull target

$24

p=25%

Bear target

$10

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

U.S.
YARTEMLEA launch durability
MASP-2 indication-expansion study enrollment

BearKey bullets

CHMP reaffirmed its negative opinion; routine European authorization and commercialization cannot be treated as imminent.
[#IR-2026-10-16]
Development-study enrollment may slip, and starting studies does not demonstrate clinical benefit.

WatchKey bullets

European narsoplimab refusal narrows the commercial case

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $17 (p=45%)

Target spread vs base: +41% / -41%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $17 (p=45%)Bear Target: $10 (p=30%)

Commentary

Recent headlines center on the October 16 European setback; the packet does not establish a verified post-event price move from its October 23 $16.57 anchor. The prior baseline described an initial selloff, but no subsequent reversal or sustained reaction is verified here. Analyst target revisions and consensus surprise data are unavailable. Social, options, short-interest and employee measures are unavailable; zeros denote missing data, not neutral readings.

As of 2026-10-25 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

U.S. YARTEMLEA launch durability
MASP-2 indication-expansion study enrollment

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$17 / p=45% prob

Bear Target (Scenario probability)

$10 / p=30% prob

Analysis 2026-10-25 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.40

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-16
European narsoplimab refusal narrows the commercial case
After re-examination, CHMP maintained its negative opinion on European authorization for narsoplimab in TA-TMA. Routine EU commercialization should not be assumed; Omeros instead plans to pursue named-patient access where permitted. This is a realized adverse event, with residual risk to expectations rather than a pending decision. [#IR-2026-10-16] Source: https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Receives-CHMP-Negative-Opinion-Following-Re-Examination-of-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx
Prob 100.00% • Move -10.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

U.S. YARTEMLEA launch durability
2026-12-31
Q2 net product revenue was $28.5 million versus $9.9 million in Q1, and operating cash flow was positive $4.1 million. Subsequent commercial disclosure must show whether demand and cash conversion persist beyond the initial launch period. The August 10-Q confirms the reporting period; no next-results date is confirmed. [#IR-2026-08-12] [#10-Q-2026-08-12] Source: https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results/default.aspx
Prob 55% • Move 15% • Priced-in 50%

Long-term Catalysts

Months to a year

MASP-2 indication-expansion study enrollment
2026-12-31
Omeros expects enrollment to begin by year-end in studies of YARTEMLEA for hyperinflammatory ARDS and prevention of severe pediatric TA-TMA. Enrollment would establish development progress, not efficacy; timing and funding remain execution risks. [#IR-2026-08-12] [#IR-2026-10-16] Sources: https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results/default.aspx ; https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Receives-CHMP-Negative-Opinion-Following-Re-Examination-of-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx
Prob 55% • Move 5% • Priced-in 30%

Risks

CHMP reaffirmed its negative opinion; routine European authorization and commercialization cannot be treated as imminent. [#IR-2026-10-16]
Development-study enrollment may slip, and starting studies does not demonstrate clinical benefit. [#IR-2026-08-12]
One full U.S. launch quarter is insufficient to establish durable demand, reimbursement realization or sustained positive operating cash flow. [#IR-2026-08-12]
The October company release identifies financing, manufacturing, reimbursement and regulatory-process risks. [#IR-2026-10-16]

Peers

Symbol	Summary
SLN	Similar market-cap biotechnology candidate, but its development-stage profile is not a direct comparator for Omeros' U.S. TA-TMA launch; avoid a mechanical valuation multiple.
KARD	Similar market-cap biopharma candidate, but product and indication comparability are unverified in this packet. Treat as a loose size reference only.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-25

Loading AI feed…

Symbol

Summary

SLN

Similar market-cap biotechnology candidate, but its development-stage profile is not a direct comparator for Omeros' U.S. TA-TMA launch; avoid a mechanical valuation multiple.

KARD

Similar market-cap biopharma candidate, but product and indication comparability are unverified in this packet. Treat as a loose size reference only.